Document is current
Any future updates will be listed below
-
Authors
Mannick, Joan B.
Lamming, Dudley W. https://orcid.org/0000-0002-0079-4467
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (AG056771, AG062328, AG061635 and AG076941)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK125859)
U.S. Department of Veterans Affairs (BX004031)
- License Information
-
More Information
Article History
Received: 7 November 2022
Accepted: 7 April 2023
First Online: 4 May 2023
Competing interests
: J.B.M. is CEO and cofounder of Tornado Therapeutics, which is developing safer, more effective mTOR inhibitors to extend human healthspan, and a former CMO of resTORbio. D.W.L. has received funding from and is a scientific advisory board member of Aeovian Pharmaceuticals, which seeks to develop new, selective mTOR inhibitors for the treatment of various diseases.
